Fluocinolone acetonide (Iluvien) extended-release intravitreal implant for diabetic macular edema

References

• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Perason AP, et al. for the FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-59
   PubMed Web of Science ®Google Scholar
• Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopa- thy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15
   PubMed Web of Science ®Google Scholar
• Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes. Incidence and risk factors. Ophthalmology 1995;102:1170-6
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-71
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Neubauer AS, Kernt M. Fluocinolone acetonide and its potential in the treatment of chroinic diabetic macular edema. Clin Ophthalmol 2013;7:503-9
   PubMedGoogle Scholar
• Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 2002;80:468-77
   PubMedGoogle Scholar
• Ansari NH, Zhang W, Fulep E, Mansour A. Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health A 1998;54:467-75
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Osterby R, Gundersen HJ. Early functional and morphologic vascular renal consequences of the diabetic state. Diabetologia 1979;17:71-6
   Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) Study. Ophthalmology 2010;117:2146-51
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Himilaton RD, et al. A prospective randomized trail of intravitreal Bevacizumab or Laser Therapy in the management of diabetic macular edema (BOLT Study): 12 month data: report 2. Ophthalmology 2010;117:1078-86
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello lP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77; e35
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (ReSolVe Study): a 12-month, randomized, controlled, double-masked, multicenter phase ii study. Diabetes Care 2010;33:2399-405
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidterfurth U, et al. The ReSToRe study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14
   PubMed Web of Science ®Google Scholar
• Machein MR, Kullmer J, Ronicke V, et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999;25:104-12
   PubMed Web of Science ®Google Scholar
• Pearson A, Levy B; and the Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multicenter clinical trial. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 1795
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20
   PubMed Web of Science ®Google Scholar
• Bringmann A, Wiedemann P. Müller glial cells in retinal disease. Ophthalmologica 2012;227:1-19
   PubMed Web of Science ®Google Scholar
• Schroder A, Palinski W, Schmid-Schonbein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991;139:81-100
   PubMed Web of Science ®Google Scholar
• Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 2007;21:3219-30
   Google Scholar
• Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998;39:2190-4
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
   PubMed Web of Science ®Google Scholar
• Schroder A, Palinski W, Schmid-Schonbein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991;139:81-100
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 1999;14:233-9
   PubMedGoogle Scholar
• Nguyen QD, Shah SM, Van Anden E, et al. Supplemental inspired oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2003;45:67-24
   Google Scholar
• Ozaki H, Yu A, Della N, et al. Hypoxia inducibile factor-1 alpha is increased in ischemic retina: temporal and spatial correlations with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-9
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. FAMOUS Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-9
   PubMed Web of Science ®Google Scholar
• Early treatment diabetic retinopathy study research group. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103:1796-806
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal Bevacizumab or Laser Therapy in the management of diabetic macular edema (BOLT Study): 12-month data: report 2. Ophthalmology 2010;117:1078-86
   PubMed Web of Science ®Google Scholar
• Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multi- center, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65
   PubMed Web of Science ®Google Scholar
• Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. for FAMOUS study group. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inset or fluocinolone acetonide implants. Ophthalmology 2013;120:583-7
   PubMed Web of Science ®Google Scholar
• Moss GP; for the International Union of Pure and Applied Chemistry and International Union of Biochemistry Joint Commission on Biochemical Nomenclature. Nomenclature of Steroids. Pure Appl Chem 1989;10:1783-822
   Google Scholar
• Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75
   PubMed Web of Science ®Google Scholar
• Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-7
   PubMed Web of Science ®Google Scholar
• Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica 2010;224 Suppl 1:25-30
   Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. FAMOUS Study Group. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013;120(3):583-7
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VeGF expression via glucocorticoid receptor in human retinal pigment epithelial (aRPe-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (caM). J Ocul Pharmacol Ther 2009;25:97-103
   PubMed Web of Science ®Google Scholar
• Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. for the FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar